Osteoarthritis: New Insights
Authors: Robert H. Palmer
Journal: Annals of Internal Medicine (2002)

Letters1 January 2002Osteoarthritis: New InsightsRobert H. Palmer, MDRobert H. Palmer, MDForest Laboratories, Inc., New York, NY 10022-4731Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-136-1-200201010-00018 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:A recommendation for osteoarthritis treatment (1) states, “The choice between a nonselective NSAID [nonsteroidal anti-inflammatory drug] and a COX-2–specific inhibitor should be made after evaluation of risk factors, particularly for upper gastrointestinal and renal toxicity.” This assumes that 1) all “NSAIDs” are similar, 2) all “COX-2s” are similar, and 3) the difference (COX-1 sparing) accounts for less toxicity. Specificity for cyclooxygenases does not determine the side effect profile of NSAIDs. Differences among COX-2s (for example, in effects on renal function) may be as great as differences from certain nonselective NSAIDs (2); the same may be true for ...References1. Hochberg MC, McAlindon T, Felson DT. Systemic and topical treatments. In: Felson DT, conference chair. Osteoarthritis: new insights. Part 2: Treatment approaches. Ann Intern Med. 2000; 113:726-29. [PMID: 11074906] Google Scholar2. Whelton A, Fort JG, Puma JA, Normandin D, Bello AE, Verburg KM. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Therap. 2001;8:85-95. [PMID: 11304662] CrossrefMedlineGoogle Scholar3. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al . Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343:1520-8. [PMID: 11087881] CrossrefMedlineGoogle Scholar4. Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, et al . Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA. 1999;282:1929-33. [PMID: 10580458] CrossrefMedlineGoogle Scholar5. Freston JW. Rationalizing cyclooxygenase (COX) inhibition for maximal efficacy and minimal adverse events. Am J Med. 1999;107:78S-88S; discussion 89S. [PMID: 10628597] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Forest Laboratories, Inc., New York, NY 10022-4731 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoOsteoarthritis: New Insights. Part 2: Treatment Approaches Conference Chair: David T. Felson , Conference Organizer: Reva C. Lawrence , Discussants: Marc C. Hochberg , Timothy McAlindon , Paul A. Dieppe , Marian A. Minor , Steven N. Blair , Brian M. Berman , James F. Fries , Morris Weinberger , Kate R. Lorig , Joshua J. Jacobs , and Victor Goldberg Osteoarthritis: New Insights David T. Felson and Timothy McAlindon Osteoarthritis: New Insights Thomas E. Lindow Osteoarthritis: New Insights David D. Waddell Osteoarthritis: New Insights Paul J. Rosch Metrics Cited byWogonoside attenuates the articular cartilage injury and the infiltration of Th1/Th2-type cytokines in papain-induced osteoarthritis in rat model via inhibiting the NF-κB and ERK1/2 activation 1 January 2002Volume 136, Issue 1Page: 87-88KeywordsCyclooxygenase 2Mucous membranesNSAIDsOsteoarthritisPlateletsSafetySafety studiesSpecificityToxicityUlcers ePublished: 1 January 2002 Issue Published: 1 January 2002 Copyright & PermissionsCopyright © 2002 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...